Protocol Ledger

NCT03937635 · Phase III · RECRUITING

Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma

Interventional Phase III clinical trial protocol NCT03937635 sponsored by ECOG-ACRIN Cancer Research Group in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2019-09-16 Enrollment: 288 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT03937635
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)288 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT03937635
Protocol FieldVerified Registry Value
NCT IdentifierNCT03937635
Consolidated Lead SponsorECOG-ACRIN Cancer Research Group
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment288 participants (ESTIMATED)
Registered Start Date2019-09-16
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI